Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784963 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03784963 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 35 participants.
The verdict
NCT03784963, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study evaluates the efficacy of high-dose fish oil in decreasing rates of gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. Half of the patients without history of bleeding will receive fish oil while the other half will not. Half of the patients with history of bleeding will receive fish oil while the other half will not. Markers of angiogenesis and inflammation, as well as changes in the microbiome will be assessed in each group.
Interventions
- OTHER Placebo
- DRUG Omega 3 fatty acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03784963
The ClinicalTrials.gov registry entry for NCT03784963 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03784963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03784963 about?
NCT03784963 is a clinical study titled "Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD". This study evaluates the efficacy of high-dose fish oil in decreasing rates of gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. Half of the patients without history of bleeding will receive fish oil while the other half will not. Half of the patients with h...
What is the current status of trial NCT03784963?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-01-23. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03784963?
The interventions under investigation include: Placebo (OTHER), Omega 3 fatty acids (DRUG).
Who is sponsoring clinical trial NCT03784963?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.